[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options]
- PMID: 17578604
- DOI: 10.1007/s00482-007-0552-5
[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options]
Abstract
The platinum derivative oxaliplatin is widely used in colorectal cancer. Its side effects differ from those of the other platinum compounds cisplatin and carboplatin. An acute, painful hyperexcitability syndrome (HES) accompanied by cold induced paresthesia, dysesthesia and myotonia is unique to oxaliplatin, whereas a chronic, peripheral sensory neuropathy (PSN) can be caused by all platinum compounds. It is believed that HES is the result of peripheral nerve hyperexcitability as a consequence of voltage-gated sodium channel dysfunction, which may be caused by calcium level imbalance. Therapeutic options for HES are the administration of calcium and magnesium, the serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine and the thiophosphate amifostine.
Similar articles
-
Clinical management of oxaliplatin-associated neurotoxicity.Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46. doi: 10.3816/ccc.2005.s.006. Clin Colorectal Cancer. 2005. PMID: 15871765 Review.
-
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.Ann Oncol. 2012 Jan;23(1):200-205. doi: 10.1093/annonc/mdr045. Epub 2011 Mar 22. Ann Oncol. 2012. PMID: 21427067 Clinical Trial.
-
Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.Clin Neurophysiol. 2018 Mar;129(3):694-706. doi: 10.1016/j.clinph.2017.11.015. Epub 2017 Nov 26. Clin Neurophysiol. 2018. PMID: 29233604
-
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.J Oncol Pharm Pract. 2010 Dec;16(4):280-2. doi: 10.1177/1078155209355849. Epub 2009 Dec 16. J Oncol Pharm Pract. 2010. PMID: 20015928
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
Cited by
-
Assessment of neuropathic pain in cancer patients.Curr Pain Headache Rep. 2009 Aug;13(4):282-7. doi: 10.1007/s11916-009-0045-6. Curr Pain Headache Rep. 2009. PMID: 19586591 Review.
-
Attenuation of activity in an endogenous analgesia circuit by ongoing pain in the rat.J Neurosci. 2010 Oct 13;30(41):13699-706. doi: 10.1523/JNEUROSCI.2867-10.2010. J Neurosci. 2010. PMID: 20943910 Free PMC article.
-
Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels.Curr Neuropharmacol. 2021;19(11):1937-1951. doi: 10.2174/1570159X19666210119153047. Curr Neuropharmacol. 2021. PMID: 33463473 Free PMC article. Review.
-
[Procedure for certification of QST laboratories].Schmerz. 2009 Feb;23(1):65-9. doi: 10.1007/s00482-008-0771-4. Schmerz. 2009. PMID: 19184121 German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical